Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2026 08:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany...
May 18, 2026 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE,...
May 18, 2026 07:00 ET | Source: Byondis B.V.

Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development

Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...
May 18, 2026 02:00 ET | Source: Byondis B.V.

Byondis Establishes Scientific Advisory Board of Recognized Leaders in Oncology Research and ADC Development

Global experts in antibody-drug conjugate (ADC) development, oncology clinical development and early-phase trial design, appointed to support advancement of Byondis’ differentiated ADC pipeline and a...
May 18, 2026 00:00 ET | Source: NovalGen Ltd.

NovalGen Appoints Dr Laurent Fischer as Chair of the Board

NovalGen appoints Dr Laurent Fischer as Chair of the Board of Directors with immediate effect.
May 17, 2026 15:30 ET | Source: Novartis Pharma AG

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12,...
May 15, 2026 09:49 ET | Source: BCC Research LLC

AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment

How chronic disease prevalence, infectious disease testing, AI investment, personalized medicine and regulatory change are shaping the diagnostics industry
May 15, 2026 08:27 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...
May 14, 2026 09:27 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer

Grand Cayman, Cayman Islands, May 14, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
May 14, 2026 08:41 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...